| Clinical data | |
|---|---|
| Other names | SR121463 |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| ECHA InfoCard | 100.211.853 |
| Chemical and physical data | |
| Formula | C33H45N3O8S |
| Molar mass | 643.80 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Satavaptan (INN; developmental code nameSR121463, former tentative brand nameAquilda) is avasopressin V2 receptorantagonist[1] which was investigation bySanofi-Aventis and was under development for the treatment ofhyponatremia. It was also being studied for the treatment ofascites.[2] Development was discontinued in 2009.[3]
Thisdrug article relating to thecardiovascular system is astub. You can help Wikipedia byexpanding it. |